Treatment of aggressive non-Hodgkin's lymphomas.

The aim of the study was to evaluate overall survival in patients with diagnosis DLBCL, comparing CHOP chemotherapy plus rituximab with CHOP alone, and standard plus intensive regimens (BEAM). Above mentioned regimens were compared in high risk patient, who were identified according to the CD10 expression with factors of IPI. 27 patients with diagnosis of diffuse large B-cell lymphomas were under observation.